Exelixis Stock Drops 15.7% Amid Biotech Sector Volatility

Exelixis Inc. (NASDAQ: EXEL) saw a 15.7% decline in its stock price, settling at $37.42. The biopharmaceutical firm focuses on cancer treatments, with flagship molecules like cabozantinib and Cotellic. Despite the drop, Exelixis has robust financial health, with a trailing twelve-month revenue of $2.3 billion, a net margin of 27.99%, and a debt-to-equity ratio of 0.09. However, insider selling and competitive pressures in the biotechnology industry are potential concerns.

Exelixis Inc. (NASDAQ: EXEL) experienced a significant decline in its stock price, falling by 15.7% to settle at $37.42. The biopharmaceutical company, which specializes in cancer treatments, reported its second-quarter earnings on Tuesday. The drop in share price was primarily attributed to the company's decision to discontinue the development of its experimental cancer drug zanzalintinib in a head-and-neck cancer trial [1].

Exelixis reported total revenues of $568.3 million for the quarter ended June 30, 2025, including $520.2 million in net product revenues from cabozantinib (Cabometyx) and $48.2 million in collaboration revenues. Net product revenues for cabozantinib were approximately 2% below the consensus estimate, but they represented a 20% increase compared to the same quarter last year [1].

Despite the revenue shortfall, Exelixis maintained its full-year 2025 guidance, projecting total revenues between $2.25 billion and $2.35 billion, with net product revenues between $2.05 billion and $2.15 billion. The company stated that the decision to halt development of zanzalintinib in HNSCC was based on strategic considerations, including prioritization of other indications with greater potential for success and commercial opportunity [1].

Exelixis's financial health remains robust, with a trailing twelve-month revenue of $2.3 billion, a net margin of 27.99%, and a debt-to-equity ratio of 0.09. However, insider selling and competitive pressures in the biotechnology industry are potential concerns.

The broader biotech sector is showing signs of recovery, with contract research organizations (CROs) reporting better-than-expected second-quarter profits. Companies such as Danaher Corp, Medpace, IQVIA Holdings Inc, ICON Plc, and Thermo Fisher have posted strong results, indicating a rebound in biotech and pharmaceutical spending after a cautious stretch driven by tighter sector financing [2].

The global oncology drugs market is set for steady growth, predicted to expand at a 6.87% CAGR from 2025 to 2032, reaching USD 364.81 billion by 2032. Key drivers include the global rise in cancer cases and increased drug development. North America leads, bolstered by chronic disease prevalence and key partnerships [3].

References:
[1] https://finance.yahoo.com/news/exelixis-fall-over-12-revenue-114904476.html
[2] https://www.reuters.com/business/healthcare-pharmaceuticals/contract-research-firms-strong-earnings-signal-stabilizing-biotech-pharma-2025-07-24/
[3] https://finance.yahoo.com/news/oncology-drugs-market-insights-competitive-145000374.html